Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | IL2 | P60568 | 3/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449982 | 0.88 | IL2 (0.63) | ABCB1ABCC1LMNAIL2DEGS1 | |
| SCHEMBL438951 | 0.87 | IL2 (0.56) | ABCB1ABCC1IL2DEGS1WNT3A | |
| Hydrochloric Acid SCHEMBL450224 | 0.86 | IL2 (0.55) | ABCB1ABCC1IL2DEGS1WNT3A | |
| SCHEMBL8239024 | 0.83 | IL2 (0.54) | LMNAIL2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2813073 | 0.82 | IL2 (0.47) | IL2DYRK1ACDC7ROCK2CDK8 | |
| SCHEMBL2816823 | 0.82 | IL2 (0.56) | IL2DYRK1ACDC7ROCK2CDK8 | |
| SCHEMBL2811821 | 0.81 | IL2 (0.72) | IL2DEGS1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2815969 | 0.79 | IL2 (0.49) | IL2DEGS1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2814582 | 0.79 | IL2 (0.49) | IL2ALDH1A1SMN1; SMN2NPC1PKM | |
| SCHEMBL11911923 | 0.79 | IL2 (0.65) | LMNAIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | claimed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR3, TSLP | ABCB1 1397/4885ABCC1 1193/4885LMNA 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.